These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 20456344

  • 1. Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab.
    Downs AM.
    Br J Dermatol; 2010 Aug; 163(2):433-4. PubMed ID: 20456344
    [No Abstract] [Full Text] [Related]

  • 2. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies.
    Santos-Juanes J, Coto-Segura P, Mas-Vidal A, Galache Osuna C.
    Br J Dermatol; 2010 May; 162(5):1144-6. PubMed ID: 20222926
    [No Abstract] [Full Text] [Related]

  • 3. Consecutive use of different biological therapies in the treatment of psoriasis.
    Costanzo A, Papoutsaki M, Mazzotta A, Chimenti S.
    Br J Dermatol; 2007 Aug; 157(2):394. PubMed ID: 17553044
    [No Abstract] [Full Text] [Related]

  • 4. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
    Woolf RT, Smith CH, Robertson K, Barker JN.
    Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
    [No Abstract] [Full Text] [Related]

  • 5. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies.
    Castiñeiras I, Fernández-Diaz L, Juárez Y, Lueiro M.
    J Dermatol; 2012 Aug; 39(8):730-1. PubMed ID: 22364316
    [No Abstract] [Full Text] [Related]

  • 6. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Leman J, Burden AD.
    Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
    [Abstract] [Full Text] [Related]

  • 7. Diagnosing latent tuberculosis infection in patients with psoriasis under antitumour necrosis factor-α treatment: every new solution breeds new doubts.
    Sánchez-Moya AI, Daudén E.
    Br J Dermatol; 2011 Jan; 164(1):208-9. PubMed ID: 21054332
    [No Abstract] [Full Text] [Related]

  • 8. Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study.
    Gniadecki R, Bang B, Sand C.
    Br J Dermatol; 2016 May; 174(5):1145-6. PubMed ID: 26522308
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
    Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A, ACCEPT Study Group.
    N Engl J Med; 2010 Jan 14; 362(2):118-28. PubMed ID: 20071701
    [Abstract] [Full Text] [Related]

  • 10. Combination therapy of biologics with traditional agents in psoriasis.
    Guenther LC.
    Skin Therapy Lett; 2011 Jun 14; 16(6):1-3. PubMed ID: 21833461
    [Abstract] [Full Text] [Related]

  • 11. Switching biologics for psoriasis.
    Ormerod AD.
    Br J Dermatol; 2010 Oct 14; 163(4):667-9. PubMed ID: 20854399
    [No Abstract] [Full Text] [Related]

  • 12. Infliximab: efficacy in psoriasis.
    Arsiwala S.
    Indian J Dermatol Venereol Leprol; 2013 Jul 14; 79 Suppl 7():S25-34. PubMed ID: 23974692
    [Abstract] [Full Text] [Related]

  • 13. Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients.
    Sorensen EP, Fanucci KA, Saraiya A, Volf E, Au SC, Argobi Y, Mansfield R, Gottlieb AB.
    J Drugs Dermatol; 2015 Aug 14; 14(8):893-8. PubMed ID: 26267736
    [Abstract] [Full Text] [Related]

  • 14. [Up-date on the use of infliximab in dermatology. Introduction].
    Sánchez-Carazo J.
    Actas Dermosifiliogr; 2008 Jul 14; 99 Suppl 4():1. PubMed ID: 19080984
    [No Abstract] [Full Text] [Related]

  • 15. Early videocapillaroscopic changes of the psoriatic skin after anti-tumour necrosis factor alpha treatment.
    De Angelis R, Gasparini S, Bugatti L, Filosa G.
    Dermatology; 2005 Jul 14; 210(3):241-3. PubMed ID: 15785057
    [No Abstract] [Full Text] [Related]

  • 16. [Intermittent treatment regimens and the rational (efficient) use of biologic agents in psoriasis].
    Moreno-Ramírez D.
    Actas Dermosifiliogr; 2011 May 14; 102(4):241-3. PubMed ID: 21481332
    [No Abstract] [Full Text] [Related]

  • 17. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis.
    Takahashi MD, Castro LG, Romiti R.
    Br J Dermatol; 2007 Oct 14; 157(4):828-31. PubMed ID: 17711530
    [No Abstract] [Full Text] [Related]

  • 18. Practical experience of biologics for treatment of very severe psoriasis: a retrospective case cohort study of patients with a baseline Psoriasis Area and Severity Index greater than 20.
    Ponnambath N, Kalavala M, Anstey AV, Piguet V, Ingram JR.
    Clin Exp Dermatol; 2016 Jan 14; 41(1):95-6. PubMed ID: 25817265
    [No Abstract] [Full Text] [Related]

  • 19. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-α therapy in psoriasis but do not necessarily predict treatment failure.
    Golberg O, Osborne JE, Hutchinson PE.
    Br J Dermatol; 2011 Feb 14; 164(2):459-60. PubMed ID: 20973773
    [No Abstract] [Full Text] [Related]

  • 20. Hair regrowth following TNF-α blockade in coexisting psoriasis vulgaris and alopecia areata.
    Ono S, Miyachi Y, Arakawa A.
    Eur J Dermatol; 2013 Feb 14; 23(4):537. PubMed ID: 24047580
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.